DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Tekturna (Aliskiren Hemifumarate) - Published Studies

 
 



Tekturna Related Published Studies

Well-designed clinical trials related to Tekturna (Aliskiren)

Effect of naproxen and acetaminophen on blood pressure lowering by ramipril, valsartan and aliskiren in hypertensive patients. [2013]

Aliskiren effect on plaque progression in established atherosclerosis using high resolution 3D MRI (ALPINE): a double-blind placebo-controlled trial. [2013]

Comparison of the effects of aliskiren/valsartan in combination versus valsartan alone in patients with stage 2 hypertension. [2012]

Long-Term Safety and Tolerability of the Oral Direct Renin Inhibitor Aliskiren with Optional Add-On Hydrochlorothiazide in Patients with Hypertension: A Randomized, Open-Label, Parallel-Group, Multicentre, Dose-Escalation Study with an Extension Phase. [2011.10.13]

Aliskiren as add-on therapy in the treatment of hypertensive diabetic patients inadequately controlled with valsartan/HCT combination: a placebo-controlled study. [2011.10.01]

Neurohumoral effects of aliskiren in patients with symptomatic heart failure receiving a mineralocorticoid receptor antagonist: the Aliskiren Observation of Heart Failure Treatment study. [2011.07]

Associations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study. [2011.07]

Effect of aliskiren addition to amlodipine on ankle edema in hypertensive patients: a three-way crossover study. [2011.06]

Peripheral and central blood pressure responses of combination aliskiren/hydrochlorothiazide and amlodipine monotherapy in African American patients with stage 2 hypertension: the ATLAAST trial. [2011.05]

Aliskiren in combination with losartan reduces albuminuria independent of baseline blood pressure in patients with type 2 diabetes and nephropathy. [2011.05]

Orange and apple juice greatly reduce the plasma concentrations of the OATP2B1 substrate aliskiren. [2011.05]

Efficacy and safety of aliskiren-based dual and triple combination therapies in US minority patients with stage 2 hypertension. [2011.03]

Comparison of aliskiren/hydrochlorothiazide combination therapy with hydrochlorothiazide monotherapy in older patients with stage 2 systolic hypertension: results of the ACTION study. [2011.03]

Itraconazole, a P-glycoprotein and CYP3A4 inhibitor, markedly raises the plasma concentrations and enhances the renin-inhibiting effect of aliskiren. [2011.03]

Comparative efficacy and safety of aliskiren and irbesartan in patients with hypertension and metabolic syndrome. [2011.03]

Aliskiren and the calcium channel blocker amlodipine combination as an initial treatment strategy for hypertension control (ACCELERATE): a randomised, parallel-group trial. [2011.01.22]

Rationale and design of the multicentre, randomized, double-blind, placebo-controlled Aliskiren Trial on Acute Heart Failure Outcomes (ASTRONAUT). [2011.01]

Impact of prolonged antihypertensive duration of action on predicted clinical outcomes in imperfectly adherent patients: comparison of aliskiren, irbesartan and ramipril. [2011]

Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failuRE (ATMOSPHERE) study. [2011]

Aliskiren alone or in combination with hydrochlorothiazide in patients with the lower ranges of stage 2 hypertension: The ACQUIRE randomized double-blind study. [2010.12]

Effects of high- and low-sodium diets on ambulatory blood pressure in patients with hypertension receiving aliskiren. [2010.12]

Comparative efficacy of aliskiren monotherapy and ramipril monotherapy in patients with stage 2 systolic hypertension: subgroup analysis of a double-blind, active comparator trial. [2010.12]

Different effects of aliskiren and losartan on fibrinolysis and insulin sensitivity in hypertensive patients with metabolic syndrome. [2010.11]

Impact of baseline renal function on the efficacy and safety of aliskiren added to losartan in patients with type 2 diabetes and nephropathy. [2010.11]

Grapefruit juice greatly reduces the plasma concentrations of the OATP2B1 and CYP3A4 substrate aliskiren. [2010.09]

Aliskiren for geriatric lowering of systolic hypertension: a randomized controlled trial. [2010.09]

Optimal antiproteinuric dose of aliskiren in type 2 diabetes mellitus: a randomised crossover trial. [2010.08]

Rifampicin reduces the plasma concentrations and the renin-inhibiting effect of aliskiren. [2010.05]

Maintenance of blood-pressure-lowering effect following a missed dose of aliskiren, irbesartan or ramipril: results of a randomized, double-blind study. [2010.02]

Efficacy and safety of aliskiren in Japanese hypertensive patients with renal dysfunction. [2010.01]

Pharmacokinetics, safety and tolerability of single and multiple oral doses of aliskiren in healthy Chinese subjects: a randomized, single-blind, parallel-group, placebo-controlled study. [2010]

Optimal antiproteinuric dose of aliskiren in type 2 diabetes mellitus: a randomised crossover trial. [2010]

Efficacy and safety of aliskiren in Japanese hypertensive patients with renal dysfunction. [2010]

Aliskiren monotherapy does not cause paradoxical blood pressure rises: meta-analysis of data from 8 clinical trials. [2010]

Maintenance of blood-pressure-lowering effect following a missed dose of aliskiren, irbesartan or ramipril: results of a randomized, double-blind study. [2010]

Evaluation of the dose--response relationship of aliskiren, a direct renin inhibitor, in an 8-week, multicenter, randomized, double-blind, parallel-group, placebo-controlled study in adult patients with stage 1 or 2 essential hypertension. [2009.12]

Aliskiren monotherapy results in the greatest and the least blood pressure lowering in patients with high- and low-baseline PRA levels, respectively. [2009.09]

Aliskiren-based therapy lowers blood pressure more effectively than hydrochlorothiazide-based therapy in obese patients with hypertension: sub-analysis of a 52-week, randomized, double-blind trial. [2009.07]

Combination therapy with various combinations of aliskiren, valsartan, and hydrochlorothiazide in hypertensive patients not adequately responsive to hydrochlorothiazide alone. [2009.06]

Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. [2009.05]

Antihypertensive efficacy and tolerability of aliskiren/hydrochlorothiazide (HCT) single-pill combinations in patients who are non-responsive to HCT 25 mg alone. [2009.04]

Long-term safety, tolerability, and antihypertensive efficacy of aliskiren, an oral direct renin inhibitor, in Japanese patients with hypertension. [2009.03]

Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. [2009.01.14]

Efficacy of aliskiren/hydrochlorothiazide single-pill combinations in aliskiren non-responders. [2008.12]

Aliskiren combined with losartan in type 2 diabetes and nephropathy. [2008.06.05]

Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. [2008.05]

Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial. [2008.03]

Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension. [2007.12]

Neurohumoral effects of the new orally active renin inhibitor, aliskiren, in chronic heart failure. [2007.11]

Hormonal and hemodynamic effects of aliskiren and valsartan and their combination in sodium-replete normotensive individuals. [2007.09]

Plasma renin and the antihypertensive effect of the orally active renin inhibitor aliskiren in clinical hypertension. [2007.09]

Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. [2007.07.21]

Direct Renin inhibition with aliskiren in obese patients with arterial hypertension. [2007.05]

Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension. [2007.03.20]

Aliskiren, an orally effective Renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. [2007.01]

Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. [2007.01]

Safety and efficacy of the oral direct renin inhibitor aliskiren in elderly patients with hypertension. [2007]

Aliskiren, a novel oral renin inhibitor, provides dose-dependent efficacy and placebo-like tolerability in Japanese patients with hypertension. [2006.12]

Pharmacokinetic interactions of the oral renin inhibitor aliskiren with lovastatin, atenolol, celecoxib and cimetidine. [2005.11]

Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. [2005.03.01]

Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption. [2004.12]

Effect of the oral renin inhibitor aliskiren on the pharmacokinetics and pharmacodynamics of a single dose of warfarin in healthy subjects. [2004.10]

Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. [2003.12]

Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril. [2002.01]

Well-designed clinical trials possibly related to Tekturna (Aliskiren)

Inhibition of the renin-angiotensin system reduces the rise in serum aldosterone in acute coronary syndrome patients with preserved left ventricular function: observations from the AVANT GARDE-TIMI 43 trial. [2013]

Patients with acute coronary syndromes and elevated levels of natriuretic peptides: the results of the AVANT GARDE-TIMI 43 Trial. [2010]

Aldosterone status associated with insulin resistance in patients with heart failure--data from the ALOFT study. [2009.12]

Could renin inhibition be the next step forward in the treatment of diabetic kidney disease? [2008.10.07]

Conformational changes in prorenin during renin inhibition in vitro and in vivo. [2006.03]

Other research related to Tekturna (Aliskiren)

Differential effects of aliskiren/amlodipine combination and high-dose amlodipine monotherapy on endothelial function in elderly hypertensive patients. [2014]

Addition of aliskiren to Angiotensin receptor blocker improves ambulatory blood pressure profile and cardiorenal function better than addition of benazepril in chronic kidney disease. [2013]

Pharmacokinetics, safety profile, and efficacy of aliskiren in pediatric patients with hypertension. [2013]

Effect of imidapril versus ramipril on urinary albumin excretion in hypertensive patients with type 2 diabetes and microalbuminuria. [2013]

Aliskiren reduces home blood pressure and albuminuria in patients with hypertensive nephrosclerosis. [2013]

Efficacy of aliskiren and valsartan in hypertensive patients with albuminuria: a randomized parallel-group study. [2013]

Aliskiren alone or in combination with hydrochlorothiazide in Hispanic/Latino patients with systolic blood pressure 160 mm Hg to <180 mm Hg (Aliskiren Alone or in Combination with Hydrochlorothiazide in Patients with Stage 2 Hypertension to Provide Quick Intensive Control of Blood Pressure [ACQUIRE] substudy). [2012]

Comparative efficacy of aliskiren/valsartan vs valsartan in nocturnal dipper and nondipper hypertensive patients: a pooled analysis. [2012]

Influence of diabetes on efficacy of aliskiren, losartan or both on left ventricular mass regression. [2012]

Aliskiren in patients with diabetes: a systematic review. [2012]

The effect of combination treatment with aliskiren and blockers of the renin-angiotensin system on hyperkalaemia and acute kidney injury: systematic review and meta-analysis. [2012]

Effects of aliskiren on QT duration and dispersion in hypertensive patients with type 2 diabetes mellitus. [2012]

Addition of aliskiren to olmesartan ameliorates tubular injury in chronic kidney disease patients partly by reducing proteinuria. [2012]

Pharmacokinetics and pharmacodynamics of aliskiren/hydrochlorothiazide single-pill combination tablets and free combination of aliskiren and hydrochlorothiazide. [2012]

Long-term safety and tolerability of the oral direct renin inhibitor aliskiren with optional add-on hydrochlorothiazide in patients with hypertension: a randomized, open-label, parallel-group, multicentre, dose-escalation study with an extension phase. [2011.12.01]

Comparison of aliskiren/hydrochlorothiazide combination therapy and amlodipine monotherapy in patients with stage 2 systolic hypertension and type 2 diabetes mellitus. [2011.12]

Efficacy and tolerability of the single-pill combination of aliskiren 300 mg/amlodipine 10 mg in hypertensive patients not controlled by olmesartan 40 mg/amlodipine 10 mg. [2011.11.28]

EFFECTS OF ALISKIREN ON QT DURATION AND DISPERSION IN HYPERTENSIVE PATIENTS WITH TYPE 2 DIABETES MELLITUS. [2011.11.10]

Comparative efficacy and safety of combination aliskiren/amlodipine and amlodipine monotherapy in African Americans with stage 2 hypertension and obesity or metabolic syndrome. [2011.11]

Left ventricular systolic and diastolic function, remodelling, and clinical outcomes among patients with diabetes following myocardial infarction and the influence of direct renin inhibition with aliskiren. [2011.09.29]

Efficacy and safety of aliskiren, a direct renin inhibitor, compared with ramipril in Asian patients with mild to moderate hypertension. [2011.09.08]

Comparative efficacy and safety of combination aliskiren/amlodipine and amlodipine monotherapy in African Americans with stage 2 hypertension. [2011]

Peripheral and central blood pressure responses of combination aliskiren/hydrochlorothiazide and amlodipine monotherapy in African American patients with stage 2 hypertension: the ATLAAST trial. [2011]

Effect of telmisartan addition to amlodipine on ankle edema development in treating hypertensive patients. [2011]

Efficacy and safety of aliskiren-based dual and triple combination therapies in US minority patients with stage 2 hypertension. [2011]

Aliskiren vs. angiotensin receptor blockers in hypertension: meta-analysis of randomized controlled trials. [2011]

Aliskiren: a review of its use as monotherapy and as combination therapy in the management of hypertension. [2010.10.22]

Effects of High- and Low-Sodium Diets on Ambulatory Blood Pressure in Patients With Hypertension Receiving Aliskiren. [2010.09.27]

Different Effects of Aliskiren and Losartan on Fibrinolysis and Insulin Sensitivity in Hypertensive Patients with Metabolic Syndrome. [2010.09.02]

Impact of Baseline Renal Function on the Efficacy and Safety of Aliskiren Added To Losartan in Patients with Type 2 Diabetes and Nephropathy. [2010.08.06]

Aliskiren ameliorates chlorhexidine digluconate-induced peritoneal fibrosis in rats. [2010.04]

Inhibition of the renin angiotensin aldosterone system: focus on aliskiren. [2010.02]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014